Topics

Articles

Nine drugs from leading manufacturers will participate in HRSA’s new 340B rebate model pilot program, set to begin in 2026, which aims to evaluate a rebate-based framework for future drug pricing models amid ongoing industry litigation.

Health Resources & Services Administration Announces Initial Drugs Apart of 340B Rebate Model Pilot Program 

The investment is aimed at boosting oral medicine manufacturing capacity.

Eli Lilly Planning $1.2 Billion Investment in Puerto Rico Manufacturing Site 

. He can be reached at nsaraceno@mjhlifesciences.com.

Podcasts

This episode of Pharma Pulse discusses Novartis’ $12 billion acquisition of Avidity Biosciences to expand its RNA therapeutics portfolio, and President Trump’s proposed 10% tariff increase on Canadian imports that could disrupt pharma supply chains.

Pharma Pulse: Novartis Buys Avidity for $12B, and Trump Threatens 10% Tariff Hike on Canada

This episode of Pharma Pulse discusses new research linking cholesterol imbalance in obesity to higher depression risk, Eli Lilly’s acquisition of Aderum Biotechnologies to strengthen its neuroscience pipeline, and Cambrex’s $120 million investment to boost US. API manufacturing capacity.

Pharma Pulse: Cholesterol Imbalance Tied to Depression Risk, Lilly Acquires Aderum Biotechnologies, and Cambrex Expands API Manufacturing

The CDMO’s latest investment will boost capacity at its Charles City, IA facility by 40%, underscoring Cambrex’s focus on reshoring drug manufacturing, advancing peptide and small molecule production, and supporting the long-term stability of the US pharma supply chain.

Cambrex Commits $120 Million to Grow US API Manufacturing 

This episode of Pharma Pulse covers Alkermes’ acquisition of Avadel Pharmaceuticals to expand its portfolio, BioNTech’s public exchange offer for CureVac to strengthen its mRNA pipeline, and a new report revealing how US medical device manufacturers are adopting digital-first models to boost compliance and patient engagement.

Pharma Pulse: Alkermes Acquires Avadel in $2.1B Deal, BioNTech Moves to Buy CureVac, and MedTech Industry Embraces Digital-First Models

The acquisition brings together two leaders in mRNA innovation, strengthening BioNTech’s oncology strategy and expanding its R&D and commercialization capabilities.

BioNTech Launches Public Exchange Offer for CureVac in $1.25B All-Stock Deal

This episode of Pharma Pulse covers MJH Life Sciences’ acquisition of BPD Healthcare to deepen its reach into hospitals and health systems, investor reaction to Novo Nordisk’s recent board changes, and Mark Cuban’s latest partnership expanding his Cost Plus Drugs platform to disrupt traditional pharmacy pricing models.

Pharma Pulse: MJH Life Sciences Expands into Health Systems, Novo Nordisk Board Shakeup Moves Markets, and Mark Cuban Grows Cost Plus Drugs Network

Videos

In the second part of her Pharma Commerce video interview Megan Wetzel, VP, product, access & affordability at CoverMyMeds, describes how high development costs, personalized treatment models, and an aging population are intensifying the imbalance.

Why Rising Complexity and R&D Costs Are Fueling Specialty Drug Spending

At HLTH 2025, the entrepreneur announced a collaboration between Cost Plus Drugs and President Trump’s TrumpRx platform aimed at improving transparency, reducing drug costs, and reshaping how Americans access their prescriptions.

Business and Finance